BioSpace News Archive

Medline announced a new version of its Optifoam® Gentle EX Foam Dressing.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the first subject was dosed in a Phase I clinical study (NCT05364840) of its oral main viral protease (Mpro) inhibitor, STI-1558.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the Phase 3 SHINE study (Abstract #7502), which demonstrated that the combination of once-daily oral IMBRUVICA® (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance.

Henrik Windahl, who recently began his employment as department manager for Dosell in iZafe Group’s wholly owned subsidiary Dosell AB, has acquired 319,941 Series B shares in the company to a value of SEK 163,534.

MannKind Corporation will showcase its mealtime insulin solutions and expanding efforts within the diabetes community at the American Diabetes Association’s 82nd Scientific Sessions, June 3-7 in New Orleans.

Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced that management will participate at two upcoming conferences in June.

Florida Cancer Specialists & Research Institute, LLS (FCS) physicians are presenting the outcomes of 33 clinical trials, the majority being Phase 1, at the 2022 American Society of Clinical Oncology (ASCO®) Annual Meeting being held June 3 – 6 in Chicago, Illinois.

Eli Lilly and Company will attend the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022.

NanoMosaic, the pioneer and leader of nanoneedle technology (MosaicNeedle™) for proteomics and multi-omics, is increasing its capabilities in neurology companion diagnostics (CDx) and future diagnostic tests, by offering a novel, highly sensitive site-specific conjugated antibody against phosphorylated Tau (Phospho-Thr217).

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), today announced that the Company plans to hold a clinical update call on June 13 after the European Hematology Association 2022 Hybrid Congress (EHA 2022) as the data is subject to meeting’s embargo policy until June 12.